Drug
Eszopiclone
Eszopiclone: highest development phase Post-Market, developed by Dr. Reddy's, Eisai, Shanghai Fosun Pharmaceutical and others. 11 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Dr. Reddy's, Eisai, Shanghai Fosun Pharmaceutical
Trials
| Drug | Phase | Indication |
|---|---|---|
| Eszopiclone NCT00247624 | Post-Market | Sleep Initiation and Maintenance Disorders |
| Eszopiclone NCT00365976 | Post-Market | Primary Insomnia |
| Eszopiclone NCT00511134 | Post-Market | Insomnia |
| ESZOPICLONE | Approved | |
| eszopiclone 3 mg NCT01710631 | Phase 3 | Primary Insomnia |
| Eszopiclone NCT00435279 | Phase 3 | Major Depressive Disorder |
| Eszopiclone NCT00368030 | Phase 3 | Insomnia |
| Eszopiclone 1 mg NCT00770510 | Phase 2/3 | Primary Insomnia |
| Eszopiclone NCT01102270 | Phase 1 | Obstructive Sleep Apnea |
| Eszopiclone Tablets 3 mg NCT02322645 | Phase 1 | Healthy |
| Eszopiclone NCT00645944 | Not Applicable | Insomnia |
Latest
Follow Eszopiclone on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.